UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 8-K
CURRENT REPORT
 _____________________________
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2018
 _____________________________
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
  _____________________________
Ireland
1-36820
98-1183488
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
20 On Hatch, Lower Hatch Street, Dublin 2, Ireland
(Address of principal executive offices)
+353 1 438-1700
(Registrant's telephone number, including area code):
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o






Item 5.07
Submission of Matters to a Vote of Security Holders
On December 7, 2018, Medtronic plc, a public limited company organized under the laws of Ireland (the "Company"), held its 2018 Annual General Meeting of Shareholders in order to: (1) elect, by separate resolutions, ten directors, each to hold office until the 2019 Annual General Meeting of the Company and until his or her successor is elected; (2) ratify, in a non-binding vote, the re-appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2019 and authorize, in a binding vote, the Company's Board of Directors, acting through the Audit Committee, to set the auditor's remuneration; and (3) approve, in a non-binding advisory vote, named executive officer compensation.
At the close of business on October 9, 2018, the record date of the Annual General Meetings, 1,348,097,639 Company ordinary shares were outstanding and entitled to vote. The holders of a total of 1,167,256,445 ordinary shares were present at the Annual General Meeting, either in person or by proxy, which total was not less than a majority of the issued and outstanding ordinary shares entitled to vote and thus constituted a quorum.
The final voting results and the votes used to determine the results for each proposal are set forth below:
1.
The shareholders elected each of the ten nominees to the Board of Directors, to hold office until the 2019 Annual General Meeting of the Company and until his or her successor is elected, as follows:
 
For
 
For (Percent of Votes Cast)
 
Against
 
Against (Percent of Votes Cast)
 
Abstain
 
Broker Non-Vote
Richard H. Anderson
1,021,491,798

 
96.455
 
37,544,220

 
3.545
 
1,699,418

 
106,521,009

Craig Arnold
1,047,774,181

 
98.978
 
10,818,536

 
1.022
 
2,142,719

 
106,521,009

Scott C. Donnelly
1,030,213,627

 
98.564
 
15,011,448

 
1.436
 
15,510,361

 
106,521,009

Randall Hogan, III
1,051,043,291

 
99.286
 
7,561,742

 
0.714
 
2,130,403

 
106,521,009

Omar Ishrak
1,014,458,704

 
96.354
 
38,383,046

 
3.646
 
7,893,686

 
106,521,009

Michael O. Leavitt
1,042,012,108

 
98.434
 
16,573,606

 
1.566
 
2,149,722

 
106,521,009

James T. Lenehan
1,040,286,942

 
98.276
 
18,246,684

 
1.724
 
2,201,810

 
106,521,009

Elizabeth Nabel, M.D.
1,056,903,052

 
99.812
 
1,995,577

 
0.188
 
1,836,807

 
106,521,009

Denise M. O'Leary
1,038,157,191

 
98.034
 
20,819,936

 
1.966
 
1,758,309

 
106,521,009

Kendall J. Powell
958,557,138

 
90.551
 
100,020,460

 
9.449
 
2,157,838

 
106,521,009

2.
The shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2019 and authorized, in a binding vote, the Company's Board of Directors, acting through the Audit Committee, to set the auditor's remuneration.
 
Votes
 
Percent of Votes Cast
For
1,132,796,195

 
97.221
Against
32,374,414

 
2.779
Abstain
2,085,836

 
N/A
Broker Non-Vote
N/A

 
N/A
3.
The shareholders approved, on a non-binding advisory basis, the compensation awarded to the Company's named executive officers.
 
Votes
 
Percent of Votes Cast
For
1,013,790,059

 
96.007
Against
42,161,520

 
3.993
Abstain
4,783,857

 
N/A
Broker Non-Vote
106,521,009

 
N/A






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDTRONIC PUBLIC LIMITED COMPANY
 
 
 
 
 
 
 
 
By
 
/s/ Bradley E. Lerman
Date: December 11, 2018
 
 
 
 
 
Bradley E. Lerman
 
 
 
 
 
 
Senior Vice President, General Counsel and Corporate Secretary